Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Free Cash Flow: 2013-2025

Historic Free Cash Flow for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $47.2 million.

  • Amphastar Pharmaceuticals' Free Cash Flow rose 2.31% to $47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year decrease of 33.44%. This contributed to the annual value of $172.3 million for FY2024, which is 18.58% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Free Cash Flow stood at $47.2 million, which was up 88.74% from $25.0 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Free Cash Flow peaked at $63.1 million during Q2 2024, and registered a low of -$4.7 million during Q3 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Free Cash Flow had a median value of $45.9 million in 2023 and averaged $37.7 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Free Cash Flow slumped by 246.41% in 2021 and then spiked by 1,879.94% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Free Cash Flow (Quarterly) stood at $33.6 million in 2021, then plummeted by 73.44% to $8.9 million in 2022, then surged by 61.75% to $14.4 million in 2023, then grew by 15.19% to $16.6 million in 2024, then rose by 2.31% to $47.2 million in 2025.
  • Its Free Cash Flow stands at $47.2 million for Q3 2025, versus $25.0 million for Q2 2025 and $24.4 million for Q1 2025.